Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib

Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor approved for the treatment of myelofibrosis and for polycythemia patients who are resistant or intolerant to hydroxyurea. We report a 72 year-old man patient with polycythemia vera who developed multiple cutaneous squamous cell carcinomas (cSCC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Dermatol
Main Authors: March-Rodriguez, Álvaro, Bellosillo, Beatriz, Álvarez-Larrán, Alberto, Besses, Carles, Pujol, Ramon M, Toll, Agustí
Formato: Artigo
Idioma:Inglês
Publicado em: The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2019
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7992689/
https://ncbi.nlm.nih.gov/pubmed/33911570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5021/ad.2019.31.2.204
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados